Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
Clinical trial NCT07762716 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07762716
- Sponsor
- BreakBio Corp
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2030-09-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.